{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:33:31Z","timestamp":1791941611477,"version":"4.3.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>IDH2 mutations occur in a small subset of intrahepatic cholangiocarcinoma and currently lack approved targeted therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>We report a post-transplant patient with IDH2-mutant intrahepatic cholangiocarcinoma who developed recurrent disease following multiple treatments for hepatocellular carcinoma and subsequent liver transplantation. Comprehensive genomic profiling revealed an IDH2 p. R172K mutation. Given limited treatment options and contraindications to immunotherapy, off-label treatment with the dual IDH1\/2 inhibitor vorasidenib was initiated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The patient achieved a durable radiographic and molecular response, with a reduction in circulating tumor DNA and a partial response by RECIST criteria sustained for approximately 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights the potential clinical relevance of IDH-directed therapy in IDH2-mutant cholangiocarcinoma and demonstrates feasibility in an immunosuppressed post-transplant setting. These findings are hypothesis-generating and support further evaluation of IDH inhibition in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag228","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:45:22Z","timestamp":1781178322000},"source":"Crossref","is-referenced-by-count":2,"title":["Clinical and molecular response to vorasidenib in post-transplant patient with IDH2-mutant intrahepatic cholangiocarcinoma"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-2416","authenticated-orcid":false,"given":"Vivian V","family":"Altiery De Jesus","sequence":"first","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore, MD, 21231,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-3223","authenticated-orcid":false,"given":"Timothy","family":"McMahon","sequence":"additional","affiliation":[{"name":"Department of Radiology, Johns Hopkins University , Baltimore, MD, 21231,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7534-0952","authenticated-orcid":false,"given":"Sara E","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Cellular & Molecular Medicine, Johns Hopkins School of Medicine , Baltimore, MD, 21231,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8184-3346","authenticated-orcid":false,"given":"Daniel J","family":"Zabransky","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore, MD, 21231,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4401-0748","authenticated-orcid":false,"given":"Mark","family":"Yarchoan","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore, MD, 21231,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0125-2405","authenticated-orcid":false,"given":"Marina","family":"Baretti","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore, MD, 21231,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2026062812113596500_oyag228-B1","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"2026062812113596500_oyag228-B2","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/cr.2012.51","article-title":"The mechanisms of IDH mutations in tumorigenesis","volume":"22","author":"Ye","year":"2012","journal-title":"Cell Res"},{"key":"2026062812113596500_oyag228-B3","doi-asserted-by":"crossref","first-page":"eadl6173","DOI":"10.1126\/science.adl6173","article-title":"Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity","volume":"385","author":"Wu","year":"2024","journal-title":"Science"},{"key":"2026062812113596500_oyag228-B4","doi-asserted-by":"crossref","first-page":"10208","DOI":"10.3389\/bjbs.2021.10208","article-title":"Isocitrate dehydrogenase IDH1 and IDH2 mutations in human cancer: prognostic implications for gliomas","volume":"79","author":"Murugan","year":"2022","journal-title":"Br J Biomed Sci"},{"key":"2026062812113596500_oyag228-B5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"key":"2026062812113596500_oyag228-B6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.humpath.2020.09.013","article-title":"Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants","volume":"106","author":"Dogan","year":"2020","journal-title":"Hum Pathol"},{"key":"2026062812113596500_oyag228-B7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026062812113596500_oyag228-B8","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"2026062812113596500_oyag228-B9","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-12-1773","article-title":"IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives","volume":"18","author":"Yang","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2026062812113596500_oyag228-B10","doi-asserted-by":"crossref","first-page":"430","DOI":"10.21037\/jgo.2017.05.04","article-title":"Current biologics for treatment of biliary tract cancers","volume":"8","author":"Zhao","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"2026062812113596500_oyag228-B11","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S2468-1253(21)00171-0","article-title":"Current and emerging therapies for advanced biliary tract cancers","volume":"6","author":"Kam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026062812113596500_oyag228-B12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3390\/cancers15010301","article-title":"The diagnostic approach towards combined hepatocellular-cholangiocarcinoma-state of the art and future perspectives","volume":"15","author":"Eschrich","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026062812113596500_oyag228-B13","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3348\/kjr.2020.0091","article-title":"Combined hepatocellular-cholangiocarcinoma: changes in the 2019 World Health Organization histological classification system and potential impact on imaging-based diagnosis","volume":"21","author":"Kim","year":"2020","journal-title":"Korean J Radiol"},{"key":"2026062812113596500_oyag228-B14","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2021.01.035","article-title":"Combined hepatocellular-cholangiocarcinoma: an update","volume":"74","author":"Beaufr\u00e8re","year":"2021","journal-title":"J Hepatol"},{"key":"2026062812113596500_oyag228-B15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/his.15081","article-title":"Multiregional analysis of combined hepatocellular-cholangiocarcinoma reveals histologic diversity and molecular clonality","volume":"84","author":"Na","year":"2024","journal-title":"Histopathology"},{"key":"2026062812113596500_oyag228-B16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s12957-020-02099-w","article-title":"Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma","volume":"18","author":"Ishii","year":"2020","journal-title":"World J Surg Oncol"},{"key":"2026062812113596500_oyag228-B17","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ajpath.2017.11.013","article-title":"Acquisition of cholangiocarcinoma traits during advanced hepatocellular carcinoma development in mice","volume":"188","author":"Li","year":"2018","journal-title":"Am J Pathol"},{"key":"2026062812113596500_oyag228-B18","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.4161\/15384101.2014.965054","article-title":"IDH mutations in liver cell plasticity and biliary cancer","volume":"13","author":"Saha","year":"2014","journal-title":"Cell Cycle"},{"key":"2026062812113596500_oyag228-B19","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2026062812113596500_oyag228-B20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2026062812113596500_oyag228-B21","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1158\/1078-0432.CCR-25-0174","article-title":"Final results from a first-in-human phase I study of the dual isocitrate dehydrogenase (IDH) 1\/2 inhibitor, LY3410738, in advanced solid tumors harboring IDH1 or IDH2 mutations","volume":"31","author":"Harding","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026062812113596500_oyag228-B22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.2026.44.2_suppl.567","article-title":"Multi-institutional retrospective study of IDH2-mutated cholangiocarcinoma","volume":"44","author":"Sahai","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026062812113596500_oyag228-B23","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1016\/j.annonc.2025.05.365","article-title":"350P IDH2-mutated cholangiocarcinoma: a case series highlighting challenges and insights","volume":"36","author":"Al Mahmasani","year":"2025","journal-title":"Ann Oncol"},{"key":"2026062812113596500_oyag228-B24","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-21-0611","article-title":"Vorasidenib, a dual inhibitor of mutant IDH1\/2, in recurrent or progressive glioma; results of a first-in-human phase I trial","volume":"27","author":"Mellinghoff","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026062812113596500_oyag228-B25","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/neuonc\/noac064","article-title":"PI3K\/AKT\/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications","volume":"24","author":"Mohamed","year":"2022","journal-title":"Neuro Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag228\/68520398\/oyag228.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag228\/68520398\/oyag228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag228\/68520398\/oyag228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:11:46Z","timestamp":1782663106000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag228\/8707344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag228","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,6]]},"article-number":"oyag228"}}